A new peer-reviewed study concluded that the mortality rate in people who used ivermectin regularly was 92 percent lower than in non-users and 84 percent lower than in irregular users.
Among the authors are Flávio Cadegiani, a board-certified endocrinologist, and Pierre Kory, an outspoken pulmonary and critical care medicine specialist, as well as president and chief medical officer of the Front Line Critical Care Alliance.
